Mystic Pharmaceuticals has received notices of allowance from the China Patent Office and the Japan Patent Office for its 'Deep Draw Container Forming Method' and 'Combination Unit Dose Dispensing Container' patent applications respectively.
The company's VersiDoser and VRx2 delivery technologies are used in combination with drugs and biologics to develop therapeutics for the treatment of ocular, CNS, neurodegenerative and infectious diseases.
Mystic president and CEO Timothy Sullivan said in the last ten years the company has innovated packaging and delivery technologies that allow the development of patient-centric pharmaceutical products.
"Japan and China along with several other global markets are high priority strategic opportunities for Mystic enhanced pharmaceutical drug/device combined products," Sullivan added.
"These latest international patents reflect our long term commitment to developing the global market opportunity for our technology and products."
Both the company's delivery platforms use new unit dose packaging and patient-centric dispensers that can be configured for precision self-administration of therapeutics for ophthalmic, systemic nasal, nose to brain, sublingual, oral and dermal applications.
With the help of the company's delivery platform technologies, pharmaceutical and biotech manufacturers will be able to develop patient-oriented products that can extend or establish market exclusivity and competitive differentiation for new or existing drugs and biologics.
